Venus Medtech (启明医疗) IPO Trading: Allocation and Buy-Level
Venus Medtech, the dominant player in the heart valve replacement segment in China, raised USD 311 million at HKD 33.0 per share. In this insight,...
497 Views
Venus Medtech IPO: Fairly Valued and More Room for Share Price to Grow
In our previous insight on Venus Medtech IPO Venus Medtech IPO: First Mover Advantage in Chinese TAVR Market to Support Growth , we discussed the...
533 Views
Venus Medtech IPO: Valuation Tempting at the Low-End
Venus MedTech (2500 HK) is a leading transcatheter heart valve medical device company in China. Venus has launched a Hong Kong IPO to raise up to...
520 Views
Venus Medtech (启明医疗) IPO: Valuation Still OK at the High End
Venus Medtech launched book building today to raise up to USD 331 million to list in Hong Kong. The deal attracted five cornerstone investors who...
592 Views
Venus Medtech (启明医疗) Pre-IPO: Thoughts on Valuation
Venus Medtech (Hangzhou) is a dominant player in the heart valve replacement devices market in China. The company started pre-marketing for a USD...
518 Views